The company hasn't given up. They believe there is signal here, and that with Ariana's help a phase 2/3 can be designed to tease that signal out. I think most of your questions are right. I've got side to add. One is, why no week-57 update on the P300 (3A) signal?
They've substituted dose dependency with concentration dependency, and by doing so there is a small improvement in the apparent r-squared off the efficacy correlation but not enough to hang a hat on. Ariana's work is not done. And yes, I don't get the MMSE slope either.